| Name | phosphoric acid,pyridine-3,4-diamine |
|---|---|
| Synonyms |
Amifampridine phosphate
3,4-Diaminopyridine phosphate UNII-8HF8FIN815 Firdapse Zenas |
| Description | Amifampridine (3,4-Diaminopyridine) phosphate is an orally active potassium channel blocker (PCB), can block presynaptic potassium channels[1]. Amifampridine phosphate can be used in Lambert-Eaton myasthenic syndrome (LEMS) research[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Amifampridine phosphate treatment (Intravenous injection; 2.5 mg/kg; once) shows 1 hour plasma half-life[2]. Amifampridine phosphate treatment (Oral administration; 10 mg/kg; once) shows plasma concentrations spike[2]. Animal Model: Mice[2] Dosage: 2.5 mg/kg Administration: Intravenous injection; 2.5 mg/kg; once Result: Had a plasma half-life of about 1 hour. Animal Model: Mice[2] Dosage: 10 mg/kg Administration: Oral administration; 10 mg/kg; once Result: Exhibited a rapid spike in plasma concentrations. |
| References |
| Molecular Formula | C5H10N3O4P |
|---|---|
| Molecular Weight | 207.12400 |
| Exact Mass | 207.04100 |
| PSA | 153.23000 |
|
~%
446254-47-3 |
| Literature: Guyon, Francois; Pradeau, Dominique; Le Hoang, My Dung; Houri, Jean-Jacques Patent: US2004/106651 A1, 2004 ; Location in patent: Page 3 ; |
| Precursor 1 | |
|---|---|
| DownStream 0 | |